Bo Jian will invest $5.6 billion to acquire pharmaceutical company Apellis.

On March 31, Boehringer announced that it has agreed to invest $5.6 billion to acquire the pharmaceutical company Apellis Pharmaceuticals, expanding its treatment capabilities in immunology and rare diseases. After the completion of the transaction, Biogen will gain two approved drugs - Syfovre for treating an immune system disease that causes blindness, and Empaveli for treating blood diseases and rare kidney diseases.